Fig. 2: Combination of sorafenib and LZX-2-73 resulted in increased cell death. | Cell Death & Disease

Fig. 2: Combination of sorafenib and LZX-2-73 resulted in increased cell death.

From: Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models

Fig. 2

A LDH release and B caspase 3/7 activity were measured on MIAPaCa-2 cells, MCF-7 cells, and HepG2 cells, respectively. The cells were treated with single drugs and the drug combination for 48 h. Data are shown as mean ± SEM. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (1-way ANOVA, Dunnett’s test, compared to combinatory treatment) (n = 3). C Viability of MIAPaCa-2 cells upon a 72-h treatment with sorafenib, LZX-2-73, or their combination, in the presence or not of several cell death inhibitors. D Expression of survivin, analyzed by western blot, in response to treatment with LZX-2-73 alone or in combination with sorafenib. Data are shown as mean ± SEM. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (1-way ANOVA, Dunnett’s test, compared combinatory treatment) (n = 4).

Back to article page